TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39333909

Group type: COMPARATOR
Intervention: Anti-Spike IgG antibody levels in the control group
Number of subjects: 3693

Group type: EXPERIMENTAL
Intervention: Anti-Spike IgG antibody levels in specific populations
Number of subjects: 3693

Group type: EXPERIMENTAL
Intervention: Anti-RBD IgG antibody levels in specific populations
Number of subjects: 3693

Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies in specific populations
Number of subjects: 3693

Group type: COMPARATOR
Intervention: Cumulative probabilities of SARS-CoV-2 infections at five months after serological measurement in specific populations
Number of subjects: 3693

Group type: COMPARATOR
Intervention: Cumulative probabilities of SARS-CoV-2 infections at five months after serological measurement in control group
Number of subjects: 3693
Study: 39333930

Group type: EXPERIMENTAL
Intervention: Standard education + planning intervention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Augmented physical activity education + planning intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 30
Study: 39333981

Group type: EXPERIMENTAL
Intervention: Basic implementation strategies (educational meeting with nurses, formal implementation blueprint, develop/distribute educational materials)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Enhanced implementation strategies (all basic strategies plus auditing/providing feedback and ongoing training for nurses)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MINISTOP 3.0 app
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness evaluation of MINISTOP 3.0
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sustainability assessment of MINISTOP 3.0
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Determinants of effectiveness of MINISTOP 3.0
Number of subjects: 120
Study: 39333988

Group type: EXPERIMENTAL
Intervention: Anlotinib at 12 mg once daily (QD) and S-1 at 60 mg twice daily (BID) for 2 weeks, followed by a 1-week treatment-free interval, then maintenance therapy with S-1 monotherapy at 60 mg BID for 2 weeks, followed by a 1-week treatment-free interval until disease progression.
Number of subjects: 52
Study: 39334005

Group type: EXPERIMENTAL
Intervention: Physiologic MRI-based tumor habitat analysis following CCRT.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatiotemporal habitats of the tumor evaluated using diffusion-weighted imaging and dynamic susceptibility contrast imaging.
Number of subjects: 0
Study: 39334026

Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP) augmented with transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP) augmented with closed-loop amplitude-modulated transcranial alternating current stimulation (CLAM-tACS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 39334032

Group type: EXPERIMENTAL
Intervention: CAB-LA
Number of subjects: 621

Group type: COMPARATOR
Intervention: Oral PrEP
Number of subjects: 621
Study: 39334042

Group type: EXPERIMENTAL
Intervention: Improvisational music therapy for 12 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Support as usual
Number of subjects: 200
Study: 39334053

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (98.7% of patients) including risperidone (83.6%) with a mean dose of 8.0 ± 5.9 mg/day
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Combination of antipsychotics with benzodiazepines (34.5%)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Combination of antipsychotics with antidepressants (14.4%)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Combination of antipsychotics with antidepressants and benzodiazepines (25.9%)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Antipsychotic monotherapy (17.9%)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 317
Study: 39334075

Group type: EXPERIMENTAL
Intervention: Nursing-led educational program
Number of subjects: 60
Study: 39334106

Group type: EXPERIMENTAL
Intervention: Digital (smartphone application) and printed (brochure) tools
Number of subjects: 236

Group type: COMPARATOR
Intervention: Printed brochure alone (usual service)
Number of subjects: 236
Study: 39334111

Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis awareness
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Willingness to use Pre-exposure prophylaxis
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Prior use of Pre-exposure prophylaxis
Number of subjects: 324
Study: 39334117

Group type: COMPARATOR
Intervention: Systematic nurse-led CGA (arm 1)
Number of subjects: 634

Group type: COMPARATOR
Intervention: GP-led CGA (arm 2)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Standard care (arm 3)
Number of subjects: 634
Study: 39334118

Group type: EXPERIMENTAL
Intervention: CRC screening decision aid
Number of subjects: 42
Study: 39334120

Group type: EXPERIMENTAL
Intervention: Problem-solving-based psychological intervention administered face-to-face (PSPI-P)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Problem-solving-based psychological intervention by telephone multiconference (PSPI-M)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Problem-solving-based psychological intervention via smartphone app (PSPI-A)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Usual care control group (UCCG)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Problem-solving-based psychological intervention (all formats)
Number of subjects: 212
Study: 39334129

Group type: EXPERIMENTAL
Intervention: Bivalirudin plus a post-PCI high-dose infusion for 2-4 hours
Number of subjects: 6016

Group type: COMPARATOR
Intervention: Heparin monotherapy
Number of subjects: 6016

Group type: EXPERIMENTAL
Intervention: Bail-out GPI
Number of subjects: 6016

Group type: COMPARATOR
Intervention: Heparin with bail-out GPI
Number of subjects: 6016
Study: 39334156

Group type: EXPERIMENTAL
Intervention: Early childhood development (ECD) sessions offered in 25 sites (T)
Number of subjects: 9408

Group type: EXPERIMENTAL
Intervention: ECD sessions with take-home play materials in Cycle 2 (T+)
Number of subjects: 9408

Group type: COMPARATOR
Intervention: Existing child health and nutrition program (PARN)
Number of subjects: 9408
Study: 39334184

Group type: EXPERIMENTAL
Intervention: Pandemic-induced isolation
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Pre-pandemic pain interference
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Social isolation interventions
Number of subjects: 188
Study: 39334205

Group type: EXPERIMENTAL
Intervention: Immunosuppressive or cytotoxic therapy
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Oral steroids
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: FVC % predicted
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: DLco % predicted
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: St. George's Respiratory Questionnaire total score
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 491
Study: 39334218

Group type: EXPERIMENTAL
Intervention: Daily bilateral hamstring stretching exercises for six weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Post-cessation (four weeks after stopping stretching)
Number of subjects: 26
Study: 39334224

Group type: EXPERIMENTAL
Intervention: Goal-directed tranexamic acid administration (Group-GDT)
Number of subjects: 764

Group type: COMPARATOR
Intervention: Preemptive tranexamic acid administration (Group-P)
Number of subjects: 764
Study: 39334260

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (AZI) 20 mg/kg bodyweight administered at 6 weeks, 9 months, and 15 months of age
Number of subjects: 20560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20560

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (AZI)
Number of subjects: 20560
Study: 39334264

Group type: EXPERIMENTAL
Intervention: Recently stopped users (n=122)
Number of subjects: 990

Group type: COMPARATOR
Intervention: E-cigarette non-users (n=621)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Sustained users (n=187)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Recently started users (n=60)
Number of subjects: 990
Study: 39334275

Group type: EXPERIMENTAL
Intervention: AR ultrasound (AR-US)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard ultrasound (S-US)
Number of subjects: 47
Study: 39334310

Group type: EXPERIMENTAL
Intervention: Spiritual heart-centred meditation (Christian or Islamic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (Mindfulness-Based Stress Reduction - MBSR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 39334317

Group type: EXPERIMENTAL
Intervention: Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex, IFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cryoprecipitated antihemophilic factor (cryo AHF)
Number of subjects: 0
Study: 39334335

Group type: EXPERIMENTAL
Intervention: Chronic periodontitis with head and neck cancer post-radiotherapy (CP + HNC post-RT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Chronic periodontitis without head and neck cancer (CP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 150
Study: 39334347

Group type: EXPERIMENTAL
Intervention: Decision support tools (DAs)
Number of subjects: 25
Study: 39334395

Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39334411

Group type: EXPERIMENTAL
Intervention: Prolonged Slow Expiration Technique (PSET)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 42
Study: 39334432

Group type: EXPERIMENTAL
Intervention: Supervised and self-monitored exercise program (NorEx)
Number of subjects: 17
Study: 39334468

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 1.2 MIE q.i.d. for 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 1.2 MIE q.i.d. for 4 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 1.2 MIE q.i.d. for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 1.2 MIE q.i.d. for 6 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 1.2 MIE q.i.d. for 7 days
Number of subjects: 0
Study: 39334472

Group type: EXPERIMENTAL
Intervention: Web-based, self-guided positive emotion regulation intervention (ORCHID)
Number of subjects: 300
Study: 39337015

Group type: EXPERIMENTAL
Intervention: Nociception Coma Scale-Revised with Personalized Painful Stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Stimulation
Number of subjects: 0
Study: 39337333

Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocyte (TIL) therapy (lifileucel)
Number of subjects: 0
Study: 39337423

Group type: EXPERIMENTAL
Intervention: Nutraceutical supplementation (olive (poly)phenol, vitamin C, and vitamin B preparation)
Number of subjects: 0
Study: 39338117

Group type: EXPERIMENTAL
Intervention: Manual Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39339676

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) adherence in women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) adherence in men
Number of subjects: 0
Study: 39339791

Group type: EXPERIMENTAL
Intervention: Daily orange consumption, dosage not specified, duration not specified
Number of subjects: 0
Study: 39339810

Group type: EXPERIMENTAL
Intervention: Probiotics and micronutrients
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 48
Study: 39340109

Group type: EXPERIMENTAL
Intervention: B.1.351 vaccine
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 208
Study: 39340164

Group type: EXPERIMENTAL
Intervention: DMT-harmine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 39340233

Group type: EXPERIMENTAL
Intervention: Glycine powder air-abrasive debridement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ultrasonic instrumentation
Number of subjects: 30
Study: 39340493

Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 1038
Study: 39340688

Group type: EXPERIMENTAL
Intervention: Colistin (CMS) administered at a dosage of 6.75 MUI q12 after a 9 MIU loading dose.
Number of subjects: 20
Study: 39340691

Group type: EXPERIMENTAL
Intervention: Celecoxib plus standard PD treatment (levodopa/carbidopa)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard PD treatment (levodopa/carbidopa)
Number of subjects: 60
Study: 39340711

Group type: EXPERIMENTAL
Intervention: Finerenone (10 mg and 20 mg)
Number of subjects: 504
Study: 39340758

Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg orally for 26 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 39341033

Group type: EXPERIMENTAL
Intervention: multicomponent exercise emphasizing progressive resistance training
Number of subjects: 570

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 570
Study: 39341091

Group type: EXPERIMENTAL
Intervention: NAC prediction model using linear support vector machine (SVM)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Radiomics-based nomograms
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Expression analysis of NAC responders
Number of subjects: 131
Study: 39341368

Group type: EXPERIMENTAL
Intervention: Etranacogene dezaparvovec gene therapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Exogenous FIX infusion
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: No or a single FIX infusion
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Postoperative management
Number of subjects: 29
Study: 39341405

Group type: EXPERIMENTAL
Intervention: N protein-based vaccine (50 µg)
Number of subjects: 5229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5229
Study: 39341436

Group type: EXPERIMENTAL
Intervention: OmniaSecure defibrillation lead
Number of subjects: 0
Study: 39341482

Group type: EXPERIMENTAL
Intervention: Penn Medicine Healthy Heart intervention
Number of subjects: 2420

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2420
Study: 39341700

Group type: EXPERIMENTAL
Intervention: ctDNA analysis using FoundationOne Liquid CDx and FoundationOneMonitor assays
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Early ctDNA changes at day 15/22
Number of subjects: 109
Study: 39341942

Group type: EXPERIMENTAL
Intervention: Teleneonatal resuscitation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Routine resuscitation
Number of subjects: 51
Study: 39342143

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MEANING)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 55

Group type: COMPARATOR
Intervention: Both conditions (Mindfulness and Usual care)
Number of subjects: 55
Study: 39342159

Group type: EXPERIMENTAL
Intervention: Dysphagia at hospital admission
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Older age
Number of subjects: 2054

Group type: COMPARATOR
Intervention: NIHSS score
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Charlson Comorbidity Index (CCI) score
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Hypertension
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Atrial fibrillation
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Diabetes
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Non-smoking status
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Myocardial infarction
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Heart failure
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Peripheral arterial disease
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Severe chronic liver disease
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Kidney disease
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Overall CCI
Number of subjects: 2054
Study: 39342204

Group type: EXPERIMENTAL
Intervention: Individually-prescribed exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Habit training resources
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic behavior prompts
Number of subjects: 0
Study: 39342220

Group type: EXPERIMENTAL
Intervention: Infant abdominal massage class by a certified instructor
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 160
Study: 39342272

Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Community Early Behavioral Intervention (EBI)
Number of subjects: 300
Study: 39342334

Group type: EXPERIMENTAL
Intervention: Horizontal guided bone regeneration (GBR) utilizing a resorbable collagen membrane and a split-thickness flap design
Number of subjects: 8
Study: 39342346

Group type: EXPERIMENTAL
Intervention: bilateral erector spinae blockade
Number of subjects: 70

Group type: COMPARATOR
Intervention: left sided serratus anterior plane block plus subcostal TAP blocks
Number of subjects: 70
Study: 39342378

Group type: EXPERIMENTAL
Intervention: Full intervention (perspective-taking workshop before dialogue)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Partial intervention (perspective-taking workshop after dialogue)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Full intervention
Number of subjects: 163

Group type: COMPARATOR
Intervention: Partial intervention
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 163
Study: 39342464

Group type: EXPERIMENTAL
Intervention: Real Cost Campaign Advertisements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39342463

Group type: EXPERIMENTAL
Intervention: SCH 727965 (dinaciclib) 50 mg/m
Number of subjects: 72
Study: 39342512

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 6001

Group type: EXPERIMENTAL
Intervention: Finerenone (LVEF <50%)
Number of subjects: 6001

Group type: EXPERIMENTAL
Intervention: Finerenone (LVEF ≥50% to <60%)
Number of subjects: 6001

Group type: EXPERIMENTAL
Intervention: Finerenone (LVEF ≥60%)
Number of subjects: 6001

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001
Study: 39342513

Group type: EXPERIMENTAL
Intervention: Ultra-low-field portable magnetic resonance imaging (ULF-pMRI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Head computed tomography (CT)
Number of subjects: 50
Study: 39342655

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 6001

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001
Study: 39342881

Group type: EXPERIMENTAL
Intervention: Normal Glucose Tolerant (NGT)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerant (IGT)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Diabetic (DM)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Longstanding-DM
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Fasting glucose levels
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: C-peptide levels
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: C-peptide
Number of subjects: 110
Study: 39342905

Group type: EXPERIMENTAL
Intervention: Mom Supports Mom (MSM) intervention
Number of subjects: 167

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 167
Study: 39343051

Group type: COMPARATOR
Intervention: Single endoscopic balloon dilation (EBD)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intensive treatment with 3 balloon dilations 3 weeks apart and/or needle-knife stricturotomy (NKSt)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: NKSt
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Concurrent intensified drug treatment
Number of subjects: 21
Study: 39343120

Group type: EXPERIMENTAL
Intervention: AVEIR DR (Abbott) leadless pacemaker system
Number of subjects: 0
Study: 39343122

Group type: EXPERIMENTAL
Intervention: CPR training (86% of respondents)
Number of subjects: 2395

Group type: EXPERIMENTAL
Intervention: CPR training in the last year (25.1%)
Number of subjects: 2395

Group type: EXPERIMENTAL
Intervention: Witnessing CPR (26.9%)
Number of subjects: 2395

Group type: EXPERIMENTAL
Intervention: General CPR training mandates
Number of subjects: 2395
Study: 39343173

Group type: EXPERIMENTAL
Intervention: Dupilumab (type 2 immune blockade)
Number of subjects: 71
Study: 39343244

Group type: EXPERIMENTAL
Intervention: Oral nirmatrelvir/ritonavir (NMV/r) 300/100 mg BID
Number of subjects: 991

Group type: COMPARATOR
Intervention: Intravenous sotrovimab (SOT)
Number of subjects: 991

Group type: COMPARATOR
Intervention: Intramuscular tixagevimab/cilgavimab (TGM/CGM)
Number of subjects: 991

Group type: COMPARATOR
Intervention: SOT
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: NMV/r
Number of subjects: 991
Study: 39343247

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 (2-Dose) administered on day 0 and day 21
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 39343309

Group type: EXPERIMENTAL
Intervention: 25 mg of psilocybin
Number of subjects: 15
Study: 39343313

Group type: EXPERIMENTAL
Intervention: Internet-based interpersonal psychotherapy (IPT) for 10 weeks with weekly therapist guidance
Number of subjects: 113

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 113
Study: 39343385

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for 52 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39343425

Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard 6-month regimen
Number of subjects: 76